Italia markets closed
Dow Jones
39.132,85 +20,69 (+0,05%) Nasdaq
17.733,57 +15,91 (+0,09%) Nikkei 225
39.667,07 +493,92 (+1,26%) EUR/USD
1,0680 -0,0035 (-0,33%) Bitcoin EUR
56.930,22 -1.184,48 (-2,04%) CMC Crypto 200
1.265,22 -18,57 (-1,45%)
NBIX Dec 2024 90.000 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 01:32PM EDT. Mercato aperto.
| Chiusura precedente | 49,00 |
| Aperto | 49,00 |
| Denaro | 53,50 |
| Domanda | 58,40 |
| Prezzo d'esercizio | 90,00 |
| Scadenza | 2024-12-20 |
| Min-Max giorno | 49,00 - 49,00 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 1 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.